Trials / Completed
CompletedNCT02113033
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- LivaNova · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Equilia® Vagal Nerve Stimulation | Vagal Nerve Stimulation synchronized with cardiac activity |
Timeline
- Start date
- 2014-10-07
- Primary completion
- 2016-02-22
- Completion
- 2016-09-20
- First posted
- 2014-04-14
- Last updated
- 2018-03-13
Locations
6 sites across 4 countries: Belgium, France, Norway, Serbia
Source: ClinicalTrials.gov record NCT02113033. Inclusion in this directory is not an endorsement.